JP2020529431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529431A5 JP2020529431A5 JP2020505827A JP2020505827A JP2020529431A5 JP 2020529431 A5 JP2020529431 A5 JP 2020529431A5 JP 2020505827 A JP2020505827 A JP 2020505827A JP 2020505827 A JP2020505827 A JP 2020505827A JP 2020529431 A5 JP2020529431 A5 JP 2020529431A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- enterococcus
- pharmaceutical composition
- bacterial strain
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 21
- 230000001580 bacterial effect Effects 0.000 claims 17
- 241000194033 Enterococcus Species 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 7
- 241000894006 Bacteria Species 0.000 claims 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 5
- 241000194030 Enterococcus gallinarum Species 0.000 claims 5
- 229960004397 cyclophosphamide Drugs 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 241000927512 Barnesiella Species 0.000 claims 3
- 241000193403 Clostridium Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 241000894007 species Species 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 244000005706 microflora Species 0.000 claims 2
- 230000004108 pentose phosphate pathway Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000016261 weight loss Diseases 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 241000701474 Alistipes Species 0.000 claims 1
- 241000204018 Anaeroplasma Species 0.000 claims 1
- 241001013579 Anaerotruncus Species 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- NGHMDNPXVRFFGS-IUYQGCFVSA-N D-erythrose 4-phosphate Chemical compound O=C[C@H](O)[C@H](O)COP(O)(O)=O NGHMDNPXVRFFGS-IUYQGCFVSA-N 0.000 claims 1
- KTVPXOYAKDPRHY-SOOFDHNKSA-N D-ribofuranose 5-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O KTVPXOYAKDPRHY-SOOFDHNKSA-N 0.000 claims 1
- 241000194029 Enterococcus hirae Species 0.000 claims 1
- 241000662772 Flavonifractor Species 0.000 claims 1
- 241000509618 Hallella Species 0.000 claims 1
- 241001112693 Lachnospiraceae Species 0.000 claims 1
- 241000160321 Parabacteroides Species 0.000 claims 1
- 241000605861 Prevotella Species 0.000 claims 1
- 241000605947 Roseburia Species 0.000 claims 1
- 241001568331 Vampirovibrio Species 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JDTUMPKOJBQPKX-GBNDHIKLSA-N sedoheptulose 7-phosphate Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O JDTUMPKOJBQPKX-GBNDHIKLSA-N 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1712857.0A GB201712857D0 (en) | 2017-08-10 | 2017-08-10 | Compositions comprising bacterial strains |
| GB1712857.0 | 2017-08-10 | ||
| GB1800866.4 | 2018-01-19 | ||
| GBGB1800866.4A GB201800866D0 (en) | 2018-01-19 | 2018-01-19 | Compositions comprising bacterial strains |
| EP18183642 | 2018-07-16 | ||
| EP18183642.0 | 2018-07-16 | ||
| PCT/EP2018/071831 WO2019030411A1 (en) | 2017-08-10 | 2018-08-10 | COMPOSITIONS COMPRISING BACTERIAL STRAINS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529431A JP2020529431A (ja) | 2020-10-08 |
| JP2020529431A5 true JP2020529431A5 (enExample) | 2021-09-16 |
Family
ID=63524238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505827A Pending JP2020529431A (ja) | 2017-08-10 | 2018-08-10 | 細菌株を含む組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200237834A1 (enExample) |
| EP (1) | EP3664824A1 (enExample) |
| JP (1) | JP2020529431A (enExample) |
| KR (1) | KR20200038970A (enExample) |
| CN (1) | CN111246866A (enExample) |
| AU (1) | AU2018312955A1 (enExample) |
| BR (1) | BR112020002212A2 (enExample) |
| CA (1) | CA3072013A1 (enExample) |
| IL (1) | IL272491A (enExample) |
| MA (1) | MA49982A (enExample) |
| MX (1) | MX392976B (enExample) |
| SG (1) | SG11202001174XA (enExample) |
| TW (1) | TW201919674A (enExample) |
| WO (1) | WO2019030411A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3768284T (lt) | 2018-03-19 | 2022-04-11 | 4D Pharma Research Limited | Enterecoccus flagelino kompozicijos, skirtos panaudoti terapijai |
| TWI731279B (zh) * | 2018-11-21 | 2021-06-21 | 葡萄王生技股份有限公司 | 發酵乳桿菌gkf3、含其之組合物及改善精神失調之用途 |
| KR102623834B1 (ko) * | 2020-07-13 | 2024-01-12 | 서울대학교병원 | 에스트로겐을 포함하는 장내 미생물총 변화를 통한 남성의 대장암 예방 또는 치료용 조성물 |
| AU2022348603A1 (en) * | 2021-09-20 | 2024-02-29 | Hudson Institute of Medical Research | Biotherapeutic enterococcus isolates |
| CN117903980B (zh) * | 2024-01-05 | 2024-10-18 | 四川大学 | 一种海氏肠球菌及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) * | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| JPH08259450A (ja) * | 1995-03-17 | 1996-10-08 | Nichinichi Seiyaku Kk | インターフェロン産生増強剤 |
| DE102010013209A1 (de) * | 2010-03-29 | 2011-09-29 | Technische Universität München | Diarrhö-Prophylaktikum |
| EP2876167A1 (en) * | 2013-11-21 | 2015-05-27 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment |
| GB201520497D0 (en) * | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA45287A (fr) * | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
-
2018
- 2018-08-10 MA MA049982A patent/MA49982A/fr unknown
- 2018-08-10 WO PCT/EP2018/071831 patent/WO2019030411A1/en not_active Ceased
- 2018-08-10 KR KR1020207006523A patent/KR20200038970A/ko not_active Ceased
- 2018-08-10 JP JP2020505827A patent/JP2020529431A/ja active Pending
- 2018-08-10 EP EP18765808.3A patent/EP3664824A1/en not_active Withdrawn
- 2018-08-10 BR BR112020002212-8A patent/BR112020002212A2/pt not_active IP Right Cessation
- 2018-08-10 MX MX2020001632A patent/MX392976B/es unknown
- 2018-08-10 AU AU2018312955A patent/AU2018312955A1/en not_active Abandoned
- 2018-08-10 CN CN201880055780.6A patent/CN111246866A/zh active Pending
- 2018-08-10 CA CA3072013A patent/CA3072013A1/en active Pending
- 2018-08-10 TW TW107128096A patent/TW201919674A/zh unknown
- 2018-08-10 SG SG11202001174XA patent/SG11202001174XA/en unknown
-
2020
- 2020-02-05 IL IL272491A patent/IL272491A/en unknown
- 2020-02-07 US US16/784,958 patent/US20200237834A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fong et al. | Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer | |
| Liu et al. | The microbiome in inflammatory bowel diseases: from pathogenesis to therapy | |
| JP2020529431A5 (enExample) | ||
| CA2787544C (en) | Probiotic composition for use in the treatment of bowel inflammation | |
| Xu et al. | Probiotic consortia and their metabolites ameliorate the symptoms of inflammatory bowel diseases in a colitis mouse model | |
| JP2019163267A5 (enExample) | ||
| US12478652B2 (en) | Bacteriophage therapy | |
| Rachmilewitz et al. | Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis | |
| Möndel et al. | Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans | |
| Kim et al. | Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice | |
| JP2019048857A5 (enExample) | ||
| US11959067B2 (en) | Bifidobacterium lactis strain for preventing or treating colitis and method for preventing or alleviating colitis | |
| JP2024523900A (ja) | 代謝性疾患の予防及び治療のためのラクトバチルスファーメンタム菌株及び制御性ｔ細胞の併用投与用途 | |
| JP2023533513A (ja) | 胃腸障害を有する伴侶動物を支援するための組成物および関連する方法 | |
| WO2020098988A1 (en) | Strains, composition and method of use | |
| JP2020529431A (ja) | 細菌株を含む組成物 | |
| US20220265733A1 (en) | Compositions comprising bacterial strains | |
| Lazarenko et al. | Imunobiotics are the novel biotech drugs with antibacterial and immunomodulatory properties | |
| CN118019543A (zh) | 解淀粉芽孢杆菌用于预防和治疗帕金森氏病的用途 | |
| Suresh et al. | Safety concerns of Probiotic use: A review | |
| Tanriover et al. | Use of probiotics in various diseases: Evidence and promises | |
| EP2785202A1 (en) | Lactobacillus paracasei subsp. paracasei, as an agent for inhibiting listeria monocytogenes in vivo infection | |
| Nag et al. | Age-Related Gut Dysbiosis and Its Impact on Inflammatory Bowel Disease | |
| Kroeker et al. | Treatment of Ulcerative Colitis | |
| Feret et al. | Manipulation of the gut microbiota: probiotics and fecal microbiota transplantation as a treatment option for recurrent Clostridium difficile infection |